Galapagos (NASDAQ:GLPG – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Friday.
Separately, Bank of America upped their price target on Galapagos from $41.00 to $44.00 and gave the company a “neutral” rating in a report on Tuesday. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $43.55.
Galapagos Stock Down 0.3 %
GLPG traded down $0.11 on Friday, reaching $41.30. The company’s stock had a trading volume of 123,233 shares, compared to its average volume of 128,258. The stock has a 50 day moving average of $38.28 and a two-hundred day moving average of $38.19. The company has a market capitalization of $2.72 billion, a price-to-earnings ratio of -18.03 and a beta of 0.32. Galapagos has a fifty-two week low of $31.86 and a fifty-two week high of $48.07.
Galapagos (NASDAQ:GLPG – Get Free Report) last announced its quarterly earnings results on Friday, November 3rd. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $1.45. The firm had revenue of $130.64 million during the quarter, compared to the consensus estimate of $116.27 million. Galapagos had a negative return on equity of 2.60% and a negative net margin of 26.25%. As a group, analysts anticipate that Galapagos will post -0.79 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Galapagos
Large investors have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in shares of Galapagos in the first quarter valued at approximately $25,000. Signaturefd LLC lifted its holdings in shares of Galapagos by 44.4% during the second quarter. Signaturefd LLC now owns 908 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 279 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Galapagos by 147.9% during the third quarter. Tower Research Capital LLC TRC now owns 1,133 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 676 shares during the period. Quadrant Capital Group LLC lifted its holdings in shares of Galapagos by 735.3% during the second quarter. Quadrant Capital Group LLC now owns 1,395 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,228 shares during the period. Finally, UBS Group AG lifted its holdings in shares of Galapagos by 58.5% during the third quarter. UBS Group AG now owns 1,509 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 557 shares during the period. 29.73% of the stock is owned by institutional investors and hedge funds.
Galapagos Company Profile
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.